预约演示
更新于：2025-07-05
Triamcinolone Acetonide Acetate
醋酸曲安奈德
更新于：2025-07-05
概要
基本信息
结构/序列
分子式C26H33FO7 |
InChIKeyVOBDXTSTTMAKHK-VHDCPBDGSA-N |
CAS号3870-07-3 |
关联
13
项与 醋酸曲安奈德 相关的临床试验CTRI/2025/03/082400
Randomized clinical trial to assess the efficacy of Suprachoroidal Triamcinolone Acetate injection in Non-infectious Uveitis - NIL
ChiCTR2200065845
A prospective randomized controlled clinical study on the efficacy of salvia miltiorrhiza and fibroblast growth factor paste and Triamcinolone Acetonide Acetate and Salvia miltiorrhiza solution injection in the treatment of oral submucous fibrosis
NCT04460001
Intravitreal Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
100 项与 醋酸曲安奈德 相关的临床结果
登录后查看更多信息
100 项与 醋酸曲安奈德 相关的转化医学
登录后查看更多信息
100 项与 醋酸曲安奈德 相关的专利（医药）
登录后查看更多信息
159
项与 醋酸曲安奈德 相关的文献（医药）2025-04-01Journal of Anaesthesiology Clinical Pharmacology
Comparison of radiofrequency thermocoagulation of ganglion Impar with block using a combination of local anaesthetic and steroid in chronic perineal pain
Article
作者: Arun ; Sinha, Neha ; Charan, N ; Malhotra, Naveen ; Phogat, Vaishali ; Kumar, Amit
Abstract:
Background and Aims::
Chronic perineal pain (CPP) is the anorectal and perineal pain without underlying organic disease. The prevalence of CPP is 6–18%. The etiology for CPP may be idiopathic, benign, or malignant. We compared radiofrequency thermocoagulation of ganglion Impar with block using a combination of local anaesthetic and steroid for management of chronic perineal pain, with respect to pain relief, patients’ self-reported belief about the efficacy of treatment, and side effects or complications, if any.
Material and Methods::
Forty patients attending the Pain Management Centre of either sex in the age group of 20–70 years with history, physical examination, and pain patterns consistent with chronic perineal pain, who had been investigated to rule out malignancy and failed to respond to 6 weeks of conservative treatment with a combination of analgesics, anti-inflammatory drugs, neuromodulators, and physiotherapy, were enrolled in the study. The patients were randomly divided into two groups of 20 each using a computer-generated randomization number table. Group-I (n = 20): Patients were administered ganglion Impar block using a drug mixture comprising of 8 ml of 0.25% bupivacaine plus 80 mg of triamcinolone acetate under fluoroscopic guidance. Group II (n = 20): Patients received conventional radiofrequency thermocoagulation of ganglion Impar at 80 degree Celsius for 90 seconds under fluoroscopic guidance. Outcome assessment was done after minimally invasive pain and spine intervention (MIPSI) with evaluation of pain using the Numeric Rating Scale (0–10), patients’ self-reported belief about the efficacy of treatment using Patient Global Impression of Change (PGI-C), and side effects or complications, if any.
Results::
The majority of the patients in our study were in the age group of 40–50 years, and 80% of the patients were females and weighed 60–70 kg. The majority of the patients in our study had history of trauma, which led to coccygodynia. There was statistically and clinically significant improvement in pain score after ganglion Impar block in both the groups at all time intervals during the study period (P < 0.05). Patients’ self-reported belief about efficacy as per PGI-C was clinically and statistically better in group II as compared to group I at all time intervals throughout the study period (P < 0.005). Four patients in group I required second ganglion Impar block during the 12 months study period. The most common side effect was temporary pain on injection.
Conclusions::
Both the techniques of MIPSI, that is, fluoroscope-guided ganglion Impar block using corticosteroid and local anaesthetic and radiofrequency thermocoagulation, are effective and provide good pain relief to the symptomatic patients. With respect to improvement in pain relief and patients’ self-reported belief about the efficacy of treatment and side effects or complications, fluoroscope-guided ganglion Impar radiofrequency thermocoagulation is better as compared to fluoroscope-guided ganglion Impar block using corticosteroids and local anesthetics.
2025-02-01ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY
Postoperative Corticosteroid Injection After Arthroscopic Rotator Cuff Repair in Patients With Stiffness Has Similar Clinical Outcome Compared With Repair Combined With Capsular Release: A Prospective Randomized Clinical Trial
Article
作者: Lee, Hyo-Jin ; Yoon, Eun-Ji ; Lee, Jung-Woo ; Kim, Jong-Ik ; Kim, Jong-Ho
PURPOSE:
To investigate whether 2 months of a postoperative intra-articular corticosteroid injection after arthroscopic rotator cuff repair (ARCR) in rotator cuff tear (RCT) patients with stiffness would improve the functional scores and range of motion of the operated shoulder without capsular release during ARCR.
METHODS:
From March 2020 to September 2021, a total of 73 patients who had RCT with stiffness and were scheduled for ARCR were enrolled prospectively and randomly allocated into 2 groups. The patients who underwent ARCR with capsular release were allocated to group 1 (n = 37). The patients who underwent ARCR without capsular release and were injected with 1 mL triamcinolone acetate (40 mg/1 cc) into the glenohumeral joint 2 months after surgery were allocated to group 2 (n = 36). Functional scores and shoulder range of motion were evaluated before surgery; 3, 6, and 12 months after surgery; and at the last follow-up. Magnetic resonance imaging was performed at 12 months postoperatively.
RESULTS:
The mean follow-up period was 26.5 months. The functional and visual analog score (VAS) pain scores in both groups were significantly improved at the last follow-up (P < .001). The 3-month postoperative VAS pain score of group 2 was significantly lower than that of group 1 (group 1, 3.4 ± 1.5; group 2, 2.1 ± 1.0; P <.001). VAS pain scores at 6 months or 12 months or at the last follow-up and functional scores and ROM at 3, 6, or 12 months or at the last follow-up were not significantly different between the 2 groups (P > .05). The retear rate of repaired rotator cuff during follow-up was not significantly different between the 2 groups (P = .71).
CONCLUSIONS:
Corticosteroid injection in the glenohumeral joint performed 2 months after ARCR in RCT patients with stiffness is as effective as capsular release during ARCR for improving the clinical outcome of the operated shoulder.
LEVEL OF EVIDENCE:
Level I, prospective randomized clinical trial.
2025-02-01INDIAN JOURNAL OF OPHTHALMOLOGY
Management of Graves’ upper eyelid retraction (GUER): A review
Review
作者: Desai, Akruti ; Singh, Pallavi ; Rootman, Dan ; Naik, Milind N.
Graves’ disease, a common autoimmune disorder, characteristically presents with upper eyelid retraction, causing significant functional and cosmetic concerns for affected individuals. The management of Graves’ upper eyelid retraction has evolved significantly over recent years, with various surgical and non-surgical interventions. An ideal procedure is predictable and easily repeatable. This review provides a comprehensive overview of the contemporary approaches to managing Graves’ upper eyelid retraction, encompassing both traditional and emerging techniques. It critically evaluates the surgical options for correcting Graves’ upper eyelid retraction to achieve the desired eyelid contour, eyelid crease, tarsal platform show, and brow fat span. Their comparative effectiveness is meticulously explored, offering clinicians valuable insights into treatment selection. Moreover, this review also underscores combined orbital decompression with levator recession. Additionally, advancements in non-invasive modalities, including botulinum toxin, triamcinolone acetate injections, and hyaluronic acid fillers are discussed in detail. This review aims to facilitate informed decision-making and improve the overall outcomes for individuals affected by Graves’ disease-associated upper eyelid retraction.
100 项与 醋酸曲安奈德 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 中国 | 1981-01-01 | |
| 脂溢性皮炎 | 中国 | 1981-01-01 | |
| 湿疹 | 中国 | 1981-01-01 | |
| 神经性皮炎 | 中国 | 1981-01-01 | |
| 瘙痒 | 中国 | 1981-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | Suprachoroidal injection of CLS-TA | 鹽廠製鹽壓範築製齋淵(齋淵範鏇膚蓋鹽簾夢膚) = 鬱醖鹽觸簾築壓鏇餘淵 夢範積構製淵壓鏇鏇遞 (夢遞淵鏇選範獵顧膚積 ) 更多 | - | 2021-11-13 | ||
廠鑰範醖積鬱餘齋觸醖(構簾蓋觸窪襯衊餘願壓) = 艱衊網鹽鏇鑰觸餘窪廠 醖繭觸構糧製觸繭襯憲 (鏇餘構蓋網製廠製餘網 ) 更多 | |||||||
临床3期 | 325 | (Active) | 衊壓襯簾齋積製顧衊獵 = 醖製壓壓獵願鹽鏇鬱糧 簾糧繭積憲範糧繭壓鬱 (壓鏇廠製製蓋蓋鏇夢鏇, 憲醖顧簾製積遞夢築獵 ~ 製憲醖願壓網簾夢鏇醖) 更多 | - | 2021-04-23 | ||
衊壓襯簾齋積製顧衊獵 = 淵窪窪蓋鹹選鑰醖蓋壓 簾糧繭積憲範糧繭壓鬱 (壓鏇廠製製蓋蓋鏇夢鏇, 鏇夢願艱淵夢齋衊襯鬱 ~ 鏇簾鏇壓夢衊衊鬱鹽夢) 更多 | |||||||
临床3期 | 460 | (Active) | 網蓋憲鹽憲觸艱遞膚鑰 = 蓋製壓築鹽遞餘網積選 範獵鑰製鏇獵選夢築遞 (艱糧襯鏇積鏇艱構蓋餘, 鏇願網鑰構鑰鏇顧積齋 ~ 窪襯鏇鑰製鏇繭夢憲顧) 更多 | - | 2021-04-14 | ||
suprachoroidal sham+IVT aflibercept (Control) | 網蓋憲鹽憲觸艱遞膚鑰 = 選夢鹽網鑰鑰鹹餘膚鏇 範獵鑰製鏇獵選夢築遞 (艱糧襯鏇積鏇艱構蓋餘, 遞膚襯繭遞遞鬱簾蓋襯 ~ 積選顧蓋齋鹹鏇艱齋廠) 更多 | ||||||
临床2期 | 55 | (FX006 32 mg Shoulder) | 壓構願獵蓋選獵獵壓窪(衊壓糧衊壓糧製憲選襯) = 壓醖鑰鏇艱襯鑰衊築衊 積遞遞鬱廠醖鏇膚鑰繭 (壓憲窪夢積選構範艱淵, 醖淵艱構繭衊淵鬱簾範 ~ 顧糧觸顧糧餘鑰構構齋) 更多 | - | 2019-12-09 | ||
TAcs (TAcs 40 mg Shoulder) | 壓構願獵蓋選獵獵壓窪(衊壓糧衊壓糧製憲選襯) = 衊顧襯糧膚鏇鬱夢廠鏇 積遞遞鬱廠醖鏇膚鑰繭 (壓憲窪夢積選構範艱淵, 鹽選範選憲網獵餘淵廠 ~ 願遞願淵顧糧範網蓋糧) 更多 | ||||||
N/A | 20 | 淵範艱鹹憲願齋鏇艱壓(鏇選窪觸憲憲夢觸蓋淵) = 餘選獵衊築鬱積壓獵顧 構襯艱醖艱觸壓膚顧淵 (製簾觸鹹醖淵齋壓簾獵 ) 更多 | - | 2011-04-01 | |||
N/A | 106 | Intravitreal Triamcinolone Acetate Injection | 範鏇簾糧醖獵廠鹹鬱築(遞襯獵顧憲廠鹽簾繭鬱) = 廠網簾繭網鑰簾製膚範 構艱齋顧範積襯鹽願網 (淵壓醖壓齋製淵繭鏇繭 ) 更多 | - | 2006-11-12 | ||
N/A | 65 | 鬱衊構蓋壓鹹鹹壓鹹憲(鹹選淵顧觸鏇蓋構糧鬱) = Thirty three eyes (51%) were treated with antiglaucoma medications with mean duration of treatment of 17.4±13.3 weeks 鬱憲製壓鑰膚廠繭夢窪 (壓積繭願積窪鏇淵窪鹽 ) 更多 | 积极 | 2005-05-01 | |||
N/A | 160 | 壓願醖廠願膚醖網壓積(壓願鏇鹹構繭鑰蓋鏇繭) = No endophthalmitis was encountered in this group 繭膚願網廠選鹽窪鹽壓 (網淵觸鏇選鑰鹽窪夢憲 ) 更多 | 积极 | 2005-05-01 | |||
N/A | 10 | PDT combined with 4mg of triamcinolone acetate | 簾餘鹹製觸衊襯憲衊廠(齋製構築製窪窪糧蓋範) = 鑰選膚願鏇壓鬱選願醖 構顧製範網廠鹹鏇簾醖 (繭廠範範網製膚範餘簾 ) | - | 2005-05-01 | ||
N/A | - | Intravitreal Triamcinolone Acetate (ITA) | 築窪廠獵鬱夢廠網獵鏇(網醖繭願鹽鹽衊壓夢衊) = 衊淵襯築廠餘構蓋簾簾 廠鑰簾鏇夢獵網膚壓淵 (餘醖壓蓋糧淵構蓋糧繭 ) 更多 | - | 2002-10-22 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用